Novo Nordisk ADR (NYSE:NVO) currently has a daily average trading volume of 8.64M but it saw 6295381 shares traded in last market. With a market cap of 211.54B USD, the company’s current market price of $62.88 came falling about -2.50 while comparing to the previous closing price of $64.49. In past 52 weeks, the stock remained buoying in the range of price level as high as $148.15 and as low as $59.32. In the recent trading on the day, stock has struck highest price mark of $62.4 while lowest mark touched by it was $64.41.
Taking a look at 20-day trading activity of Novo Nordisk ADR (NVO) gives us an average price of $68.04, while its current price level is -57.56% below from 52-week high level whereas it is 6.00% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $77.66 while that of 200 days or SMA-200 reads an average of $105.94. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.61% during that period while stretching the period over a month that decreases to 3.59%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 35.86 which implies that the stock is in neutral territory.
Over the week, NVO’s stock price is moving -3.40% down while it is -22.35% when we observe its performance for the past one month. Year-to-date it is -26.90% down and over the past year, the stock is showing a downside performance of -49.25%.
The company is expected to be releasing its next quarterly report on 2025-Feb-04, for which analysts forecasted an EPS of 6.09 while estimate for next year EPS is 26.67. In next quarter, company is expected to be making quarterly sales of $80.68B as analysts are expecting the sales for current fiscal year at $347.22B and seeing the company making $404.04B in sales next year. Moreover, analysts are in estimates of $78.19B for current-quarter revenue.
Currently, Novo Nordisk ADR’s total number of outstanding shares is 3.37B with 0.00% of that held by the insiders while 10.28% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 45.25% and return on equity (ROE) at 82.03%. It has a price to earnings ratio (P/E ratio) of 19.16 while having a 13.11 of forward P/E ratio. Stock’s beta reads 0.66. Stock has a price to book (P/B) ratio of 14.02 while price to sale or P/S ratio amounts to 5.03. Its return on asset (ROA) is 26.33% on average.
